首页> 外国专利> Recognition of tumor vasculature targeted using the Antibody L19 against Fibronectin radiolabelled ed - B

Recognition of tumor vasculature targeted using the Antibody L19 against Fibronectin radiolabelled ed - B

机译:使用抗纤连蛋白放射性标记ed-B的抗体L19识别靶向的肿瘤血管

摘要

A specific element that binds to human beings. The specific binding element is labeled with isotopes selected from a group consisting of 76Br, 77br, 123I, 124I, 131I and 211At, and includes an antigen binding site, including VH antibody and VL antibody domains, The VH domain consists of VH CDR1, VH CDR2 and VH CDR3. VH CDR3 is L19 VH CDR3 with SEQ ID No.3, VH CDR1 is L19 VH CDR1 with SEQ ID No.1, and VH CDR2 is L19 VH CDR2 with SEQ ID No.1.y donde el dominio de anticuerpo VL se selecciona opcionalmente del grupo formado por el dominio VL de L19 y un dominio VL que comprende una VL CDR1 una VL CDR2 y una VL CDR3 donde la VL CDR3 es la L19 VL CDR3 de la SEQ ID N 6 The specific binding elements include a microimmunoglobulin, a VH antibody domain and a VL antibody domain combined with es2-ch4, which are oxidized or contain a complete IgG1 antibody molecule, and the method and use of the specific binding element.
机译:与人类绑定的特定元素。特异性结合元件被选自由76Br,77br,123I,124I,131I和211At组成的组的同位素标记,并且包括抗原结合位点,包括VH抗体和VL抗体结构域,VH结构域由VH CDR1,VH组成CDR2和VH CDR3。 VH CDR3是具有SEQ ID No.3的L19 VH CDR3,VH CDR1是具有SEQ ID No.1的L19 VH CDR1,VH CDR2是具有SEQ ID No.1的L19 VH CDR2 SEQ ID N 6的特异性结合元件包括微免疫球蛋白,VH和VL CDR1或VL CDR2或VL CDR3或VL CDR3或L19 VL CDR3。氧化或包含完整的IgG1抗体分子的es2-ch4结合的IgG抗体结构域和VL抗体结构域,以及特异性结合元件的方法和用途。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号